Phase II Trial of Temodar [temozolomide] Plus O6-Benzylguanine [benzylguanine] (O6-BG) (NSC 637037) in the Treatment of Patients With Temodar-Resistant Malignant Glioma

Trial Profile

Phase II Trial of Temodar [temozolomide] Plus O6-Benzylguanine [benzylguanine] (O6-BG) (NSC 637037) in the Treatment of Patients With Temodar-Resistant Malignant Glioma

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2012

At a glance

  • Drugs Benzylguanine (Primary) ; Temozolomide (Primary)
  • Indications Anaplastic astrocytoma; Glioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jan 2009 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
    • 22 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Feb 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top